中文

iRhythm falls 31% as FDA filing slips and its raise leans on an acquisition

By · AI-assisted, human-reviewed and edited · · Updated · 15 sources · Fact-checked · 6 min read

Why is iRhythm stock down today?

iRhythm raised its 2026 revenue outlook, but only because of an acquisition; without it, the range is about 1% lower than in August. It also delayed the FDA filing for its next heart-monitoring patch to 2027 and said revenue from its Zio AT patch stopped growing. The shares fell about 31%, on a day the S&P 500 rose. Those changes are real, but no source we found explains a fall this large on their own.

What it means

What changed
iRhythm no longer plans to file Zio MCT this year, expects Zio AT to stay flat, and has trimmed its 2026 revenue outlook excluding VitalConnect.
What hasn't changed
It still expects about $1 billion of organic revenue in 2027 and mid-teens Zio Monitor growth, and it raised its 2026 margin outlook.
Next · Early January 2027 (expected)
iRhythm expects to give 2027 guidance at the J.P. Morgan Healthcare Conference; watch its assumptions for Zio AT and VitalConnect.
Move
▼ 30.7%
Price
$130.19 → $90.22
Value lost
~$1.3B
2026 revenue outlook
$890–895M
Excluding VitalConnect
$874–879M vs $880–890M
Zio AT revenue
Flat (growth expected)

Prices: Official close via Yahoo Finance and CNBC, Nov 6, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean

Closing prices on Nov 6, 2026: the official close, from Yahoo Finance and CNBC. The previous close is the official Nov 5 close. Market value uses 33,618,146 common shares on Oct 29 (10-Q cover).

Snapshot at the Nov 6, 2026 close

Enterprise value
$3.1B
Price/sales
3.6×
P/E
n/m
Price/FCF
410.9×
Revenue growth
+22%
Net debt
$91M

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $90.22 (Official close via Yahoo Finance and CNBC); 33.6 million shares (common shares on the cover page of the 10-Q filed Nov 5, 2026). n/m = not meaningful (e.g. negative earnings).

What happened

iRhythm sells wearable patches that record heart rhythm, and the analysis that goes with them. Its main product, Zio Monitor, grew again, but three things in Thursday’s report went the other way.

  • The raise came from an acquisition. iRhythm lifted its 2026 revenue outlook to $890 million to $895 million from $880 million to $890 million in August, but the new range includes about $16 million from VitalConnect, which it bought on Oct 5. Without that, the range is $874 million to $879 million, about 1% lower at the midpoint (our calculation). The full range is also below the $905.9 million consensus, Investing.com reported, without naming a vendor.
  • The filing slipped. In August, CEO Quentin Blackford said iRhythm remained focused on FDA clearance for Zio MCT in the first half of next year. Now it won’t submit the application this year and expects to file in 2027, with no date. “We recognize that this timeline has shifted multiple times,” he said.
  • Zio AT stopped growing. Revenue from it was roughly flat, against expectations of growth in line with the business. iRhythm expects flat volume and about 10% lower revenue for Zio AT in the fourth quarter, and flat revenue in 2027.

Revenue rose 14.9% to $221.6 million, just below estimates of about $222.2 million (MarketBeat, Investing.com), and below the second quarter’s $224.2 million. The adjusted EBITDA margin (earnings before interest, tax, depreciation and amortization) was 23.1%, and iRhythm raised its 2026 outlook for it to 15.5% to 16.0% from 13% to 14%. Gross margin was 74.2%, or about 72.8% excluding one-time tariff refunds (our calculation: less the roughly 1.4 points management attributed to them).

The shares fell about 12% after hours, per our screen data, and closed down about 31% at $90.22 on Friday. The fall ranks third against daily closing moves since November 2016, behind 39.5% in April 2021 and 32.9% in January 2021; the stock had already lost 27% this year through Thursday (Nasdaq closes, our calculation). Investment bank Citigroup moved to Neutral from Buy with a $124 target, MarketBeat reported.

Why the market reacted this way

The headline raise hid slower organic growth, and iRhythm’s main reasons for investors to expect faster growth moved later.

  • Growth is slowing fast. Revenue growth went from 20.1% in the second quarter to 14.9% in the third, and the outlook excluding VitalConnect implies about 10% to 12% in the fourth (our calculation; Canaccord analyst John Young, whose firm rates iRhythm Buy, put the same numbers to Blackford on the call, and he said Zio AT was the reason).
  • $1 billion now takes a pickup. iRhythm still expects its organic business to “track toward approximately $1 billion” of revenue in 2027. From the $876.5 million midpoint this year, that is about 14% growth, faster than the fourth-quarter pace, with Zio AT flat (our calculation). Finance chief Dan Wilson said it assumes mid-teens Zio Monitor growth.
  • The Zio AT problem came from the deal itself, iRhythm says. New accounts are putting off signing up because they don’t want to integrate Zio AT now and VitalConnect’s product again later. Blackford expects that to “hang around for a quarter or two.” Truist analyst Richard Newitter, whose firm had a Buy rating, asked how this wasn’t caught in due diligence; Blackford said iRhythm had anticipated a slowdown, but it slowed further than expected.
  • There is a trade-off. iRhythm is putting VitalConnect’s integration ahead of the Zio MCT filing. That gives it an FDA-cleared product now, for about $237.5 million in cash plus up to 423,334 shares (10-Q), at the cost of delaying the product it expects to replace Zio AT. It expects total gross margin above 70% in the fourth quarter including VitalConnect.
  • Legal matters remain open. iRhythm has been answering Justice Department subpoenas since 2021, and a December 2025 civil demand concerns Zio AT and its reimbursement claims. The new 10-Q adds that it met the department on Nov 4 to discuss “potential resolution pathways.” It gave no amount, and we found no source tying the fall to this. iRhythm says it has completed remediation of the issues behind the FDA warning letter, and it doesn’t know when the follow-up inspection will come.

Is a 1% organic cut enough for a 31% fall?

The sources don’t establish how much of the fall reflects the organic revenue revision or the other developments.

  • The numbers changed less than the price. The organic outlook is about 1% lower at the midpoint, the 2027 revenue goal stands and the 2026 margin outlook rose. At Thursday’s close, market value was about $4.4 billion, or 4.9 times the midpoint of 2026 revenue; at $90.22 it is about 3.4 times (our calculation). So most of the fall is investors paying less for each dollar of sales.
  • The fall deepened through the morning, from about 12% after hours to about 15% at the open, about 28% by 9:45 a.m. and about 33% by midday, per our screen data, Yahoo Finance and Nasdaq. We found no new company announcement after the 10-Q filed on Thursday evening. Same-day coverage cites the filing delay, Zio AT and analyst actions, and doesn’t explain the further slide.
  • It wasn’t the broad market. Yahoo Finance closes showed the S&P 500 up 0.3%, the Nasdaq Composite up 1.1% and the VanEck Semiconductor ETF (SMH) up 3.6%; Investing.com reported a rebound in chip stocks after Thursday’s selloff. Medical devices were weak, with the iShares U.S. Medical Devices ETF (IHI) down 2.4% and Boston Scientific, which also sells heart monitoring, down 4.2%, but far less.
  • We can’t size expectations for 2027 or Zio MCT. We found no named consensus for either, and the analyst notes aren’t public. We don’t know how much of the fall reflects a lost product timeline, doubts about $1 billion, or worry about the Justice Department.

Does this change iRhythm’s future?

What did NOT change

Zio Monitor grew ahead of iRhythm’s expectations, and it expects mid-teens growth in the fourth quarter and in 2027. iRhythm ended the quarter with $560.7 million of cash and marketable securities, before paying for VitalConnect, and added a $300 million credit line. It reiterated an adjusted EBITDA margin of at least 15% for 2027. Those are company statements.

What DID change

In August, iRhythm focused on Zio MCT clearance in the first half of 2027 and gave a revenue outlook of $880 million to $890 million; now the filing itself is in 2027 and the comparable range is $874 million to $879 million. Zio AT, which it expected to grow with the business, is now assumed flat next year. Quarterly net loss widened to $29.9 million, including a $50 million Baxter patent settlement that ends that litigation. Removing only that charge gives about $20.1 million of profit (our calculation), before the company’s other adjustments.

Our read

Our interpretation is that investors reacted to iRhythm’s growth story moving later, more than to the small change in this year’s numbers: the product meant to refresh Zio AT is delayed, Zio AT has stalled, and $1 billion now needs growth to pick up. iRhythm calls the delays temporary, and that can’t be tested until the combined platform is out. Nothing we found fully explains why the fall deepened through Friday morning.

The other view

Investment bank Needham kept a Buy rating, though it cut its target to $165 from $194, and said the purchasing delays behind Zio AT's weakness could resolve in early 2027, Investing.com reported.

Source: Investing.com: Needham cuts iRhythm stock price target on Zio AT weakness

What to watch next

Early January 2027 (expected)
iRhythm expects to give 2027 guidance at the J.P. Morgan Healthcare Conference; watch its assumptions for Zio AT and VitalConnect.
First quarter of 2027
The combined VitalConnect and Zio AT platform, which iRhythm expects to start becoming available in the middle of the quarter. Its CEO expects Zio AT's delays to last a quarter or two.
2027 (no date given)
The Zio MCT filing with the FDA. Separately, the Justice Department matters and the FDA's follow-up inspection have no announced dates.

Quick questions

What are Zio AT and Zio MCT?

Zio AT is iRhythm's wearable heart-monitoring patch that sends data during wear, a category called mobile cardiac telemetry. Zio MCT is its planned next version, designed for a longer wear period and better detection, iRhythm says. It isn't cleared by the FDA, and iRhythm expects it to eventually replace Zio AT.

Did iRhythm beat or miss on earnings?

Adjusted earnings per share were $0.82 versus a $0.02 consensus, according to FiscalAI, per MarketBeat. Investing.com instead compared the reported loss of $0.90 a share with the same estimate and called it a miss; the estimate's accounting basis wasn't specified there. The $50 million Baxter settlement is among the items adjusted figures exclude.

Updates

  • : Updated to the Nov 6 close: down 30.7% at $90.22.
  • : The path of the fall: the earlier version said about 28% near the open. The official open was $110.36, down about 15%, and the 28% was the 9:45 a.m. figure, so it now reads about 15% at the open and about 28% by 9:45 a.m.

About iRhythm: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.